Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection

Clinical Infectious Diseases

Volumn 48, Issue 2, 2009, Pages 229-238

  Dalmau, Judith ^a   Puertas, Maria Carmen ^a   Azuara, Marta ^a   Mariño, Ana ^b   Frahm, Nicole ^d   Mothe, Beatriz ^a   Izquierdo Useros, Nuria ^a   Buzón, Maria José ^a   Paredes, Roger ^a   Matas, Lourdes ^a   Allen, Todd M ^d   Brander, Christian ^a,c,d   Rodrigo, Carlos ^a   Clotet, Bonaventura ^a   Martinez Picado, Javier ^a,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Universidad de La Coruña   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EMTRICITABINE; ENFUVIRTIDE; HLA A ANTIGEN; HLA B ANTIGEN; LOPINAVIR PLUS RITONAVIR; PROTEOME; TENOFOVIR; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLELE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; BLOOD SALVAGE; BRAIN HEMORRHAGE; CANDIDA ALBICANS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CEREBROSPINAL FLUID CULTURE; CLADISTICS; COGNITIVE DEFECT; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENOTYPE; GROWTH RATE; HAEMOPHILUS INFLUENZAE; HEPATOMEGALY; HLA SYSTEM; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; LABORATORY TEST; LUNG LAVAGE; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; SEROLOGY; SEXUAL TRANSMISSION; SPUTUM ANALYSIS; SYMPTOM; T LYMPHOCYTE; TOXOPLASMA GONDII; TROPICS; VIRUS ISOLATION; VIRUS LOAD; WESTERN BLOTTING; BLOOD; CLASSIFICATION; CYTOTOXIC T LYMPHOCYTE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MONONUCLEAR CELL; PATHOLOGY; VIROLOGY;

ADOLESCENT; ADULT; CELLS, CULTURED; FEMALE; GENOTYPE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTORS, HIV; T-LYMPHOCYTES, CYTOTOXIC;

EID: 58749088944     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/595704     Document Type: Article

References (43)

1. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
2. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-64.
3. Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis 2004; 38:1447-53.
4. Munoz A, Wang MC, Bass S, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J Epidemiol 1989; 130:530-9.
5. Tersmette M, Lange JM, de Goede RE, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989; 1:983-5.
6. Dorak MT, Tang J, Penman-Aguilar A, et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004; 363:2137-9.
7. Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-8.
8. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905.
9. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-87.
10. Villena C, Prado JG, Puertas MC, et al. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol 2007; 81:4713-21.
11. Martinez-Picado J, Frost SD, Izquierdo N, et al. Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol 2002; 76:12344-8.
12. Max Planck Institut Informatik. Geno2pheno [coreceptor]. Available at: http://coreceptor.bioinf.mpi-inf.mpg.de/. 6 November 2008.
13. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1.
14. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-200.
15. Woodberry T, Suscovich TJ, Henry LM, et al. Differential targeting and shifts in the immunodominance of Epstein-Barr virus-specific CD8 and CD4 T cell responses during acute and persistent infection. J Infect Dis 2005; 192:1513-24.
16. Frahm N, Yusim K, Suscovich TJ, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007; 37:2419-33.
17. Balotta C, Bagnarelli P, Violin M, et al. Homozygous Δ32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997; 11:F67-71.
18. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
19. Morpeth S, Thielman N, Giner J, et al. Time to HIV-1 seroconversion is similar among patients with acute HIV-1 infection, but there are exceptions [abstract 389]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). 2006.
20. Chin BS, Lee SH, Kim GJ, Kee MK, Suh SD, Kim SS. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation. J Clin Microbiol 2007; 45:1659-62.
21. Abelian A, Burling K, Easterbrook P, Winter G. Hyperimmunoglobulinemia and rate of HIV type 1 infection progression. AIDS Res Hum Retroviruses 2004; 20:127-8.
22. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-502.
23. Markham RB, Wang WC, Weisstein AE, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A 1998; 95:12568-73.
24. Demarest JF, Jack N, Cleghorn FR, et al. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 2001; 17:1333-44.
25. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-8.
26. Isaksson B, Albert J, Chiodi F, Furucrona A, Krook A, Putkonen P. AIDS two months after primary human immunodeficiency virus infection. J Infect Dis 1988; 158:866-8.
27. Michael NL, Brown AE, Voigt RF, et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection - evidence for highly susceptible human hosts. J Infect Dis 1997; 175:1352-9.
28. Yu XF, Wang Z, Vlahov D, Markham RB, Farzadegan H, Margolick JB. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users. J Infect Dis 1998; 178:388-96.
29. Sheppard HW, Celum C, Michael NL, et al. HIV-1 infection in individuals with the CCR5-Δ32/Δ32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002; 29:307-13.
30. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-34.
31. Morison L, Buve A, Zekeng L, et al. HIV-1 subtypes and the HIV epidemics in four cities in sub-Saharan Africa. AIDS 2001; 15(Suppl 4):S109-16.
32. Nyambi P, Heyndrickx L, Vereecken K, et al. Predominance of infection with HIV-1 circulating recombinant form CRF02-AG in major Cameroonian cities and towns. AIDS 2002; 16:295-6.
33. Konings FA, Burda ST, Urbanski MM, Zhong P, Nadas A, Nyambi PN. Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02-AG (CRF02-AG) has a higher in vitro replicative capacity than its parental subtypes A and G. J Med Virol 2006; 78:523-34.
34. Njai HF, Gali Y, Vanham G, et al. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02-AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006; 3:40.
35. O'Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale. Trends Mol Med 2001; 7:379-81.
36. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283:1748-52.
37. Itescu S, Mathur-Wagh U, Skovron ML, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992; 5:37-45.
38. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D. Progression to AIDS in French haemophiliacs: association with HLA-B35. AIDS 1993; 7:497-500.
39. Gao X, Nelson GW, Karacki P, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344:1668-75.
40. Bienzle D, MacDonald KS, Smaill FM, et al. Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners. J Infect Dis 2000; 182:123-32.
41. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928-35.
42. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-80.
43. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.